SEHK:1952Biotechs
Everest Medicines (SEHK:1952) Wins China Approval As CARDAMYST Puts Valuation Back In Focus
China approves CARDAMYST, putting Everest Medicines in focus
Everest Medicines (SEHK:1952) just cleared a major hurdle in China, with regulators approving CARDAMYST for at home treatment of acute paroxysmal supraventricular tachycardia episodes in adults.
Despite the regulatory win, Everest Medicines shares closed at HK$31.22 after a 1 day share price return that declined 5.5%. However, the 30 day and 90 day share price returns of 10.1% and 13.9% suggest momentum has been building off a...